These activities are supported by educational grants from Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, and Servier Pharmaceuticals LLC.  

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for acute myeloid leukemia. Each event will employ an identical format that will include the following elements:

• Moderator Dr Neil Love and a featured participating clinical investigator
• Discussion of participating faculty treatment recommendations
• Review of available clinical research findings
• Community oncologist video case presentations
• Interactive audience polling and extensive Q&A

MODULE 1: Optimal Management of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients Not Eligible for Intensive Therapy

MODULE 2: Current Management Approaches for Patients with AML and a FLT3 and/or IDH Mutation

MODULE 3: Novel Induction and Maintenance Strategies for Younger Patients with AML; Promising Agents and Strategies Under Investigation

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of acute myeloid leukemia.

Learning Objectives

• Evaluate the importance of age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for patients with various presentations of acute myeloid leukemia (AML).
• Appreciate the FDA approval of venetoclax in combination with azacitidine or decitabine or lowdose cytarabine for patients with newly diagnosed AML unfit for intensive therapy, and identify individuals appropriate for treatment with his novel agent.
• Develop an understanding of the mechanisms of action of, published data with and current role for available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and an IDH1 or 2 mutation and incorporate these agents into current management algorithms.
• Reflect on available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
• Review Phase III data documenting the efficacy of CC-486 as maintenance therapy for patients with newly diagnosed AML who achieved first complete response or complete response with incomplete blood count recovery with induction chemotherapy, and consider how this novel strategy can be applied in current clinical management.
• Recall promising agents and investigational strategies under evaluation for AML, and counsel appropriately selected patients regarding clinical trial enrollment.

CE Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Daver — Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Arog Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, ImmunoGen Inc, Jazz Pharmaceuticals Inc, Novartis, Pfizer Inc, Servier Pharmaceuticals LLC, Shattuck Labs, Syndax Pharmaceuticals Inc, Trillium Therapeutics Inc; Contracted Research: AbbVie Inc, Amgen Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlycoMimetics Inc, Hanmi Pharmaceutical, ImmunoGen Inc, NovImmune SA, Pfizer Inc, Servier Pharmaceuticals LLC, Trillium Therapeutics Inc, Trovagene. Dr Fathi — Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Blueprint Medicines, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Foghorn Therapeutics, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Ipsen Biopharmaceuticals Inc, Kite, A Gilead Company, Kura Oncology, MorphoSys, NewLink Genetics, Novartis, Pfizer Inc, Seagen Inc, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc, Trillium Therapeutics Inc, Trovagene; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Servier Pharmaceuticals LLC; Data and Safety Monitoring Board/Committee: Takeda Pharmaceuticals USA Inc. Dr Olin — Advisory Committee: Astellas; Consulting Agreements: AbbVie Inc, Actinium Pharmaceuticals Inc, Amgen Inc. Dr Pratz — Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Jazz Pharmaceuticals Inc, Novartis; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Takeda Pharmaceuticals USA Inc. Dr Stock — Advisory Committee: Amgen Inc, GlaxoSmithKline, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Pfizer Inc, Pluristem Therapeutics Inc, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals Inc; Contracted Research: Pfizer Inc; Data and Safety Monitoring Board/Committee: Servier Pharmaceuticals LLC; Scientific Advisory Committee: Newave Pharmaceutical Inc. Prof Wei — Advisory Committee and Honoraria: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, MacroGenics Inc, Novartis, Pfizer Inc, Servier Pharmaceuticals LLC; Consulting Agreement: Servier; Contracted Research: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, F Hoffmann-La Roche Ltd, Novartis, Servier Pharmaceuticals LLC; Patents and Royalties: Professor Andrew Wei is an employee of the Walter and Eliza Hall Institute and is eligible for a fraction of the royalty stream related to venetoclax; Speakers Bureau: AbbVie Inc, Bristol-Myers Squibb Company, Celgene Corporation, Novartis.

SURVEY PARTICIPANTS — Daniel A Pollyea, MD, MS — Advisory Committee: AbbVie Inc, Amgen Inc, Aprea Therapeutics, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Foghorn Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlycoMimetics Inc, Jazz Pharmaceuticals Inc, Kiadis Pharma, Novartis, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AbbVie Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlycoMimetics Inc, Novartis, Syros Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Pfizer Inc, Teva Oncology; Data and Safety Monitoring Board/Committee: AbbVie Inc, GlycoMimetics Inc, Takeda Pharmaceuticals USA Inc. Eytan M Stein, MD — Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Novartis, Ono Pharmaceutical Co Ltd, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc; Contracted Research: Agios Pharmaceuticals Inc, Bayer HealthCare Pharmaceuticals, BioTheryX Inc, Bristol-Myers Squibb Company, Celgene Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Prelude Therapeutics, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, and Servier Pharmaceuticals LLC.